(Q34189435)

31 July 2017

title

Bortezomib in kidney transplantation. (English)

1 reference

31 July 2017

main subject

kidney transplantation

1 reference

Rajeev Raghavan

1

1 reference

31 July 2017

Abdallah Jeroudi

2

1 reference

31 July 2017

Katafan Achkar

3

1 reference

31 July 2017

A Osama Gaber

4

1 reference

31 July 2017

Samir J Patel

5

1 reference

31 July 2017

Abdul Abdellatif

6

1 reference

31 July 2017

publication date

27 September 2010

1 reference

Journal of transplantation

31 July 2017

published in

1 reference

31 July 2017

volume

2010

1 reference

31 July 2017

page(s)

104-112

1 reference

Creative Commons Attribution 3.0 Unported

31 July 2017

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Advances in immunosuppression for renal transplantation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Abrogation of anti-HLA antibodies via proteasome inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

The proteasome as a target for cancer therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

A phase 2 study of bortezomib in relapsed, refractory myeloma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Humoral theory of transplantation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

The effect of desensitization protocols on human splenic B-cell populations in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F698594

Bortezomib in kidney transplant desensitization: a case report.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Elimination of post-transplant donor-specific HLA antibodies with bortezomib.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952895

Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20953363

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2010/698594

1 reference

31 July 2017

1 reference

31 July 2017

1 reference